If you're having problems viewing this message, please click here for additional help.

June, 2008                                                                                                                            Home

Effects of rosiglitazone and sumatriptan in human isolated small and large coronary arteries As part of expanding our safety pharmacology portfolio, we have recently tested a range of drugs that have been highlighted by the FDA after the drug has reached the market as causing adverse cardiovascular events e.g. increased risk of MI, with the result that the drugs have either stayed on the market with additional warning/restrictions or been temporarily withdrawn. At the Asterand laboratories in Royston, UK, classical in vitro pharmacology techniques can be used to assess potential vasoconstriction in human isolated large and small coronary arteries. In addition, any inotropic (force of contraction) or chronotropic (rate of contraction) changes can be measured in human isolated atrial appendage experiments. Coronary vasoconstriction, a known side effect of some drugs such as triptans, has been demonstrated in human isolated tissues, and the aim of these current studies was to see whether the unwanted reported clinical side effects could be picked up at an earlier stage using human in vitro studies. Drugs currently being tested for potential off-target and unwanted side effects on the cardiovascular system at Royston include rosiglitazone (Avandia), sumatriptan (Imitrex, Imigran) and tegaserod (Zelnorm). Some of our initial findings will be presented at the European Pharmacology meeting (EPHAR2008) being held in Manchester between July 13-17 www.ephar2008.org.

ASTERAND SUPPORTS HUMAN DRUG DISCOVERY AND TRANSLATIONAL MEDICINE THROUGH THE PROVISION OF HIGH QUALITY WELL CHARACTERIZED HUMAN BIOMATERIALS AND PRECLINICAL RESEARCH SERVICES

Visit us at www.Asterand.com